IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Kuijjer, Marieke L ^a   Peterse, Elisabeth F P ^a   van den Akker, Brendy E W M ^a   Briaire de Bruijn, Inge H ^a   Serra, Massimo ^b   Meza Zepeda, Leonardo A ^c   Myklebost, Ola ^c   Hassan, A Bassim ^d   Hogendoorn, Pancras C W ^a   Cleton Jansen, Anne Marie ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Bone neoplasm; IGF1R; IGF1R signaling; OSI 906; Osteosarcoma; Sarcoma; Signal transduction

Indexed keywords

INSULIN RECEPTOR; LINSITINIB; MESSENGER RNA; SOMATOMEDIN C RECEPTOR; 3-(8-AMINO-1-(2-PHENYLQUINOLIN-7-YL)IMIDAZO(1,5-A)PYRAZIN-3-YL)-1-METHYLCYCLOBUTANOL; IMIDAZOLE DERIVATIVE; PYRAZINE DERIVATIVE;

ARTICLE; BONE BIOPSY; BONE DEVELOPMENT; BONE GROWTH; CANCER GRADING; CANCER INHIBITION; CANCER STEM CELL; CELL ASSAY; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TARGETING; GENE EXPRESSION; GENOME ANALYSIS; HUMAN; HUMAN CELL; IC 50; MESENCHYMAL STEM CELL; NUCLEOTIDE SEQUENCE; OSTEOBLAST; OSTEOSARCOMA; OSTEOSARCOMA CELL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; BIOSYNTHESIS; BONE TUMOR; DNA MICROARRAY; DRUG EFFECTS; MESENCHYMAL STROMA CELL; METABOLISM; PHYSIOLOGY;

BLOTTING, WESTERN; BONE NEOPLASMS; CELL PROLIFERATION; HUMANS; IMIDAZOLES; MESENCHYMAL STROMAL CELLS; NEOPLASM GRADING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOBLASTS; OSTEOSARCOMA; PYRAZINES; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

EID: 84877861065     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-245     Document Type: Article

References (55)

1. Raymond AK, Ayala AG, Knuutila S. Conventional osteosarcoma. World Health Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, 264-270. Lyon: IARC Press, Fletcher CDM, Unni KK, Mertens F.
2. Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PCW, Memon MA, Weeden S, Uscinska BM, Van Glabbeke M, Kirkpatrick A, Hauben EI, Craft AW, Taminiau AHM. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: A randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007, 99:112-128. 10.1093/jnci/djk015, 17227995.
3. Eselgrim M, Grunert H, Kuhne T, Zoubek A, Kevric M, Burger H, Jurgens H, Mayer-Steinacker R, Gosheger G, Bielack SS. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials. Pediatr Blood Cancer 2006, 47:42-50. 10.1002/pbc.20608, 16206218.
4. Cai Y, Mohseny AB, Karperien M, Hogendoorn PCW, Zhou G, Cleton-Jansen AM. Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol 2010, 220:24-33. 10.1002/path.2628, 19882675.
5. Mohseny AB, Cai Y, Kuijjer M, Xiao W, van den Akker B, De Andrea CE, Jacobs R, Ten Dijke P, Hogendoorn PCW, Cleton-Jansen AM. The activities of Smad and Gli mediated signalling pathways in high-grade conventional osteosarcoma. Eur J Cancer 2012, 48:3429-3438. 10.1016/j.ejca.2012.06.018, 22868198.
6. Rikhof B, De JS, Suurmeijer AJ, Meijer C, van der Graaf WT. The insulin-like growth factor system and sarcomas. J Pathol 2009, 217:469-482. 10.1002/path.2499, 19148905.
7. Maki RG. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol 2010, 28:4985-4995. 10.1200/JCO.2009.27.5040, 3039924, 20975071.
8. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012, 12:159-169.
9. Siddle K. Molecular basis of signaling specificity of insulin and IGF receptors: neglected corners and recent advances. Front Endocrinol (Lausanne) 2012, 3:34.
10. Foulstone E, Prince S, Zaccheo O, Burns JL, Harper J, Jacobs C, Church D, Hassan AB. Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol 2005, 205:145-153. 10.1002/path.1712, 15641016.
11. Siddle K. Signalling by insulin and IGF receptors: supporting acts and new players. J Mol Endocrinol 2011, 47:R1-R10. 10.1530/JME-11-0022, 21498522.
12. Subbiah V, Anderson P. Targeted Therapy of Ewing's Sarcoma. Sarcoma 2011, 2011:686985. 2968715, 21052545.
13. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993, 75:59-72.
14. Sutter NB, Bustamante CD, Chase K, Gray MM, Zhao K, Zhu L, Padhukasahasram B, Karlins E, Davis S, Jones PG, Quignon P, Johnson GS, Parker HG, Fretwell N, Mosher DS, Lawler DF, Satyaraj E, Nordborg M, Lark KG, Wayne RK, Ostrander EA. A single IGF1 allele is a major determinant of small size in dogs. Science 2007, 316:112-115. 10.1126/science.1137045, 2789551, 17412960.
15. Selvarajah GT, Kirpensteijn J. Prognostic and predictive biomarkers of canine osteosarcoma. Vet J 2010, 185:28-35. 10.1016/j.tvjl.2010.04.010, 20493743.
16. Kirpensteijn J, Kik M, Teske E, Rutteman GR. TP53 gene mutations in canine osteosarcoma. Vet Surg 2008, 37:454-460. 10.1111/j.1532-950X.2008.00407.x, 18986312.
17. Arora RS, Kontopantelis E, Alston RD, Eden TO, Geraci M, Birch JM. Relationship between height at diagnosis and bone tumours in young people: a meta-analysis. Cancer Causes Control 2011, 22:681-688. 10.1007/s10552-011-9740-9, 21336591.
18. Mirabello L, Pfeiffer R, Murphy G, Daw NC, Patino-Garcia A, Troisi RJ, Hoover RN, Douglass C, Schuz J, Craft AW, Savage SA. Height at diagnosis and birth-weight as risk factors for osteosarcoma. Cancer Causes Control 2011, 22:899-908. 10.1007/s10552-011-9763-2, 3494416, 21465145.
19. Kolb EA, Gorlick R. Development of IGF-IR Inhibitors in Pediatric Sarcomas. Curr Oncol Rep 2009, 11:307-313. 10.1007/s11912-009-0043-1, 19508836.
20. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, De Alava E, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, Cleton-Jansen AM, Hogendoorn PCW, Buerger H, Aigner T, Gabbert HE, Poremba C. Molecular Characterization of Commonly Used Cell Lines for Bone Tumor Research: A Trans-European EuroBoNet Effort. Genes Chrom Cancer 2010, 49:40-51. 10.1002/gcc.20717, 19787792.
21. Kuijjer ML, Rydbeck H, Kresse SH, Buddingh EP, Lid AB, Roelofs H, Burger H, Myklebost O, Hogendoorn PCW, Meza-Zepeda LA, Cleton-Jansen AM. Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data. Genes Chromosomes Cancer 2012, 51:696-706. 10.1002/gcc.21956, 22454324.
22. Cleton-Jansen AM, Anninga JK, Briaire-de Bruijn I, Romeo S, Oosting J, Egeler RM, Gelderblom H, Taminiau AHM, Hogendoorn PCW. Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. Br J Cancer 2009, 101:2064. 10.1038/sj.bjc.6605482, 2795446, 19997114.
23. Bernardo ME, Emons JAM, Karperien M, Nauta AJ, Willemze R, Roelofs H, Romeo S, Marchini A, Rappold GA, Vukicevic S, Locatelli F, Fibbe WE. Human mesenchymal stem cells derived from bone marrow display a better chondrogenic differentiation compared with other sources. Connect Tissue Res 2007, 48:132-140. 10.1080/03008200701228464, 17522996.
24. Namlos HM, Meza-Zepeda LA, Baroy T, Ostensen IH, Kresse SH, Kuijjer ML, Serra M, Burger H, Cleton-Jansen AM, Myklebost O. Modulation of the Osteosarcoma Expression Phenotype by MicroRNAs. PLoS One 2012, 7:e48086. 10.1371/journal.pone.0048086, 3485010, 23133552.
25. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004, 5:R80. 10.1186/gb-2004-5-10-r80, 545600, 15461798.
26. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3. Article3.
27. R Development Core Team R: A language and environment for statistical computing, reference index version 2.15.0 2011, Vienna, Austria, R Foundation for Statistical Computing, R Development Core Team.
28. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000, 28:27-30. 10.1093/nar/28.1.27, 102409, 10592173.
29. Goeman JJ, van de Geer SA, De KF, Van Houwelingen HC. A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 2004, 20:93-99. 10.1093/bioinformatics/btg382, 14693814.
30. Schrage YM, Briaire-de Bruijn IH, De Miranda NF, Van OJ, Taminiau AHM, Van Wezel T, Hogendoorn PCW, Bovee JVMG. Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res 2009, 69:6216-6222. 10.1158/0008-5472.CAN-08-4801, 19602594.
31. Namlos HM, Kresse SH, Muller CR, Henriksen J, Holdhus R, Saeter G, Bruland OS, Bjerkehagen B, Steen VM, Myklebost O. Global gene expression profiling of human osteosarcomas reveals metastasis-associated chemokine pattern. Sarcoma 2012, 2012:639038. 3324929, 22518090.
32. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000, 183:1-9. 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J, 10699960.
33. Conover CA. Insulin-like growth factor-binding proteins and bone metabolism. Am J Physiol Endocrinol Metab 2008, 294:E10-E14.
34. Hutchison MR, Bassett MH, White PC. SCF, BDNF, and Gas6 are regulators of growth plate chondrocyte proliferation and differentiation. Mol Endocrinol 2010, 24:193-203. 10.1210/me.2009-0228, 2802903, 19897599.
35. Scharla SH, Strong DD, Rosen C, Mohan S, Holick M, Baylink DJ, Linkhart TA. 1,25-Dihydroxyvitamin D3 increases secretion of insulin-like growth factor binding protein-4 (IGFBP-4) by human osteoblast-like cells in vitro and elevates IGFBP-4 serum levels in vivo. J Clin Endocrinol Metab 1993, 77:1190-1197. 10.1210/jc.77.5.1190, 7521341.
36. Shiozawa Y, Pedersen EA, Patel LR, Ziegler AM, Havens AM, Jung Y, Wang J, Zalucha S, Loberg RD, Pienta KJ, Taichman RS. GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia 2010, 12:116-127. 2814350, 20126470.
37. Benini S, Zuntini M, Manara MC, Cohen P, Nicoletti G, Nanni P, Oh Y, Picci P, Scotlandi K. Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma. Int J Cancer 2006, 119:1039-1046. 10.1002/ijc.21929, 16570284.
38. Chen D, Yoo BK, Santhekadur PK, Gredler R, Bhutia SK, Das SK, Fuller C, Su ZZ, Fisher PB, Sarkar D. Insulin-like growth factor-binding protein-7 functions as a potential tumor suppressor in hepatocellular carcinoma. Clin Cancer Res 2011, 17:6693-6701. 10.1158/1078-0432.CCR-10-2774, 3207018, 21908579.
39. Liao B, Hu Y, Herrick DJ, Brewer G. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 2005, 280:18517-18524.
40. Schaeffer DF, Owen DR, Lim HJ, Buczkowski AK, Chung SW, Scudamore CH, Huntsman DG, Ng SS, Owen DA. Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival. BMC Cancer 2010, 10:59. 10.1186/1471-2407-10-59, 2837867, 20178612.
41. Suvasini R, Shruti B, Thota B, Shinde SV, Friedmann-Morvinski D, Nawaz Z, Prasanna KV, Thennarasu K, Hegde AS, Arivazhagan A, Chandramouli BA, Santosh V, Somasundaram K. Insulin growth factor-2 binding protein 3 (IGF2BP3) is a glioblastoma-specific marker that activates phosphatidylinositol 3-kinase/mitogen-activated protein kinase (PI3K/MAPK) pathways by modulating IGF-2. J Biol Chem 2011, 286:25882-25890. 10.1074/jbc.M110.178012, 3138258, 21613208.
42. Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, Buck E, Foreman K, Landfair D, O'Connor M, Pirritt C, Sun Y, Yao Y, Arnold LD, Gibson NW, Ji QS. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem 2009, 1:1153-1171. 10.4155/fmc.09.89, 21425998.
43. Fulzele K, DiGirolamo DJ, Liu Z, Xu J, Messina JL, Clemens TL. Disruption of the insulin-like growth factor type 1 receptor in osteoblasts enhances insulin signaling and action. J Biol Chem 2007, 282:25649-25658. 10.1074/jbc.M700651200, 17553792.
44. Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini PL, Astolfi A, Pandini G, Lopez-Guerrero JA, Schaefer KL, Belfiore A, Picci P, Scotlandi K. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene 2011, 30:2730-2740. 10.1038/onc.2010.640, 21278796.
45. Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, Rosenfeld-Franklin M, Lerner L, Chiu MI, Wild R, Epstein D, Pachter JA, Miglarese MR. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther 2010, 9:2652-2664. 10.1158/1535-7163.MCT-10-0318, 20924128.
46. Olmos D, Tan DS, Jones RL, Judson IR. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. Cancer J 2010, 16:183-194. 10.1097/PPO.0b013e3181dbebf9, 20526094.
47. Juergens H, Daw NC, Geoerger B, Ferrari S, Villarroel M, Aerts I, Whelan J, Dirksen U, Hixon ML, Yin D, Wang T, Green S, Paccagnella L, Gualberto A. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 2011, 29:4534-4540. 10.1200/JCO.2010.33.0670, 3236653, 22025154.
48. Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP, Toner GC, Maki RG, Meyers PA, Chugh R, Ganjoo KN, Schuetze SM, Juergens H, Leahy MG, Geoerger B, Benjamin RS, Helman LJ, Baker LH. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 2011, 29:4541-4547. 10.1200/JCO.2010.34.0000, 3236654, 22025149.
49. Tap WD, Demetri G, Barnette P, Desai J, Kavan P, Tozer R, Benedetto PW, Friberg G, Deng H, McCaffery I, Leitch I, Badola S, Chang S, Zhu M, Tolcher A. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol 2012, 30:1849-1856. 10.1200/JCO.2011.37.2359, 22508822.
50. Kolb EA, Kamara D, Zhang W, Lin J, Hingorani P, Baker L, Houghton P, Gorlick R. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr Blood Cancer 2010, 55:67-75.
51. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50:1190-1197. 10.1002/pbc.21450, 18260118.
52. Houghton PJ, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wu J, Smith MA. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2010, 54:921-926. 3003867, 20166202.
53. Bagatell R, Herzog CE, Trippett TM, Grippo JF, Cirrincione-Dall G, Fox E, Macy M, Bish J, Whitcomb P, Aikin A, Wright G, Yurasov S, Balis FM, Gore L. Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. Clin Cancer Res 2011, 17:611-619. 10.1158/1078-0432.CCR-10-1731, 21127194.
54. Quek RH, Morgan JA, Shapiro G, Butrynski JE, Wang Q, Huftalen T, Jederlinic N, Wagner AJ, Demetri GD, George S. Combination mTOR+IGF-IR inhibition: Phase I trial of everolimus and CP-751871 in patients (pts) with advanced sarcomas and other solid tumors 2010, ASCO Annual Meeting.
55. Desai J, Solomon BJ, Davis ID, Lipton LR, Hicks R, Scott AM, Park J, Clemens PL, Gestone TA, Finckenstein FG. Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors 2010, ASCO Annual Meeting.